Navigation Links
Fenwal, Golden Meditech Complete Definitive Agreement to Form Joint Venture in China
Date:3/8/2011

LAKE ZURICH, Ill. and HONG KONG, March 8, 2011 /PRNewswire-Asia-FirstCall/ -- Fenwal Inc. of Lake Zurich, Illinois, and Golden Meditech Holdings Limited (stock code: 801.HK; 910801.TW) of Hong Kong announced today they have entered into a definitive agreement to form a joint venture in China that will sell advanced products and technologies for blood collection, storage and transfusion.

The joint venture is expected to be formed later this year after receiving customary commercial and regulatory approvals. The expected name of the new company will be Fenwal Jingjing Medical Technologies Ltd. (Fenwal Jingjing). Fenwal will own 51 percent of the new venture and Golden Meditech will own 49 percent.

Fenwal Jingjing will bring together advanced blood-collection, separation and storage technologies from both parent companies, and will benefit from the complementary strengths of Fenwal and Golden Meditech. Fenwal has a long history of innovation and leadership in blood technologies worldwide. Golden Meditech has expertise in serving China's unique and fast-growing health-care sector, with leadership in cord-blood banking and hospital services as well as medical-device development, manufacturing and distribution.

The joint venture will maintain an existing Fenwal office in Shanghai and establish a new operating subsidiary in Beijing, from which it will serve customers throughout China. Initially, Fenwal Jingjing will sell and distribute two key products: the Fenwal Amicus® blood-cell separator, a system used to collect platelets and other blood components such as stem cells; and the 3000H plasma exchange system, which removes toxins from the blood and was developed by a Golden Meditech subsidiary, Beijing Jingjing Medical Equipment Co. Ltd. The joint venture also will distribute related supplies and medical accessories to blood banks, cord blood banks and other medical institutions.

"Fenwal is a global pioneer and leader in advanced blood technologies," said Mr. Kam Yuen, Golden Meditech's chairman and chief executive officer. "Our combined strength and experience will facilitate the advancement of blood collection and transfusion medicine in China, while offering solutions that are tailored to the Chinese medical sector to better serve patients. This agreement is an important milestone and it's a great honor to forge this joint venture with such an excellent partner."

"Golden Meditech has quickly established a leading position in China for medical technologies and services," said Mr. Ron K. Labrum, Fenwal president and chief executive officer. "This is an important collaboration that expands our product offering, provides new resources for growth and innovation, and makes us a more attractive partner for other medical companies looking to enter into or accelerate growth in China."

The two companies had previously announced their intent to form a joint venture under a framework agreement signed in 2009.

About FenwalFenwal, Inc. is a global medical technology company dedicated to ensuring the continued availability, safety and effectiveness of blood - medicine's most vital natural resource. Fenwal offers the broadest range of products for the automated and manual collection, filtration, separation, storage and transfusion of blood and its components. The company was founded in 1949. Today, Fenwal products and advanced blood technologies are used to help treat patients on six continents. Fenwal, Inc. is based in Lake Zurich, Illinois. For more information, please visit www.fenwalinc.com.

About Golden MeditechGolden Meditech Holdings Limited is China's leading integrated healthcare device and service provider, and the first medical device company that is publicly listed outside of the PRC on the Stock Exchange of Hong Kong Limited (HKEx). Golden Meditech is a first-mover in China, having established leading positions in medical devices and healthcare services over the years, thanks to its strengths in innovation and commercial expertise and the ability to identify and realize emerging market opportunities. Going forward, the group will continue to pursue a leading position in niche market segments in China's healthcare industry both through organic growth and strategic expansion. For more information, please visit www.goldenmeditech.com.

Media Contacts:Fenwal

Golden MeditechTanya Tyska

Dennis Haikuan Lu+1-847-550-2732

+852-3605-8138tanya.tyska@fenwalinc.com

dennis@goldenmeditech.com
'/>"/>

SOURCE Golden Meditech; Fenwal, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Fenwal, GenesisBPS Enter Agreement for Blood-Specialty Products
2. Golden Meditech Acquires Remaining Stake in Chinese Herbal Medicine Business
3. Golden Meditech to Form Strategic Alliance with Long Bon International
4. Golden Meditech as First Chinese Healthcare Enterprise to Obtain Approval for Taiwan Depositary Receipts Offering
5. Golden Meditech Announces Plan to Issue Taiwan Depository Receipts
6. Golden Meditech Announces Annual Results for FY 2009/10
7. Samplify Systems Completes Series B Funding
8. Aerie Pharmaceuticals Completes $30 Million Series B Financing to Fund Further Development of Innovative Glaucoma Product Portfolio
9. Amgen Completes Acquisition of BioVex
10. MicroConstants Completes Installation of Latest LC/MS/MS Technology to Achieve Improved Sensitivity in Bioanalytical Method Development
11. Elektas Oncology-Specific MOSAIQ Receives Complete ONC-ATCB EMR Certification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... 2016 Alzheimer Diagnostic Tests - Medical ... Medical Devices sector report , "Alzheimer Diagnostic Tests ... overview of Alzheimer Diagnostic Tests currently in pipeline ... the pipeline products with comparative analysis of the ... reviews major players involved in the pipeline product ...
(Date:2/8/2016)... LONDON , Feb.8, 2016 Aesthetic Devices ... GlobalData,s Medical Devices sector report, "Aesthetic Devices - Medical ... Devices currently in pipeline stage. This ... secondary and primary research by GlobalData,s team of industry ... be removed or altered based on the availability and ...
(Date:2/8/2016)... TOKYO and FAIRFIELD, N.J. ... (Otsuka) and Medimetriks Pharmaceuticals, Inc. (Medimetriks) today announced that ... exclusive development and commercialization rights for OPA-15406 in the ... agreement also provides manufacturing rights.  OPA-15406 is a topical, ... for atopic dermatitis. --> ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to ... are derived from a cluster of melanin when exposed to sunlight. Although most moles ... a lifetime of embarrassment. Historically, mole removal has involved a painful, often ...
(Date:2/8/2016)... ... 2016 , ... Guruji Mahendra Kumar Trivedi is offering 3 days of accelerated ... his birthday on February 10th. During this time, people can achieve better health, ... 250,000 people from over 40 different countries as an “ordinary man with an extraordinary ...
(Date:2/8/2016)... ... 08, 2016 , ... According to research by the National ... technicians to be certified or obtain continuing education. To increase patient awareness of ... Your Mouth?” campaign to inform dentists and patients about the possible lack of ...
(Date:2/7/2016)... , ... February 07, 2016 , ... Women's Excellence staff, ... Wear Red Day. National Wear Red Day is the first Friday each February ... disease and stroke cause 1 in 3 deaths among women each year – more ...
(Date:2/7/2016)... Scottsdale, AZ (PRWEB) , ... February 07, 2016 ... ... & Neck and Facial Plastics, has added Kybella® to his medical and surgical ... is a newly approved FDA injectable medication used as a non-surgical alternative for ...
Breaking Medicine News(10 mins):